Overview

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Status:
RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Phase:
PHASE1
Details
Lead Sponsor:
Alessa Therapeutics Inc.
Collaborator:
National Cancer Institute (NCI)
Treatments:
enzalutamide